HCW-9201

N/A

Report date: 2025/02/12 10:56:06

Base Information

Drug NameHCW-9201
Drug Alias NameHCW-9201WU-NK-101W NK
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Memory like cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived +[4] 
Mechanisms of ActionNatural killer cell replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWugen Inc
China Registration ClassN/A

Develop Information

Active CompaniesHCW Biologics IncWugen IncAlpha Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHead and Neck NeoplasmsColorectal Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A